296 related articles for article (PubMed ID: 18930517)
41. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease.
Lau AC; Duong TT; Ito S; Yeung RS
Arthritis Rheum; 2009 Jul; 60(7):2131-41. PubMed ID: 19565485
[TBL] [Abstract][Full Text] [Related]
42. Persistent endothelial damage after intravenous immunoglobulin therapy in Kawasaki disease.
Sakurai Y; Takatsuka H; Onaka M; Takada M; Nishino M
Int Arch Allergy Immunol; 2014; 165(2):111-8. PubMed ID: 25401215
[TBL] [Abstract][Full Text] [Related]
43. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease.
Abe J; Jibiki T; Noma S; Nakajima T; Saito H; Terai M
J Immunol; 2005 May; 174(9):5837-45. PubMed ID: 15843588
[TBL] [Abstract][Full Text] [Related]
44. Marker of T-cell activation is elevated in refractory Kawasaki disease.
Suzuki H; Suenaga T; Takeuchi T; Shibuta S; Yoshikawa N
Pediatr Int; 2010 Oct; 52(5):785-9. PubMed ID: 20487370
[TBL] [Abstract][Full Text] [Related]
45. The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy.
Leucht S; Uttenreuther-Fischer MM; Gaedicke G; Fischer P
Clin Immunol; 2001 Apr; 99(1):18-29. PubMed ID: 11286538
[TBL] [Abstract][Full Text] [Related]
46. The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease.
Chang LS; Lo MH; Li SC; Yang MY; Hsieh KS; Kuo HC
Oncotarget; 2017 Jan; 8(2):2044-2052. PubMed ID: 27893416
[TBL] [Abstract][Full Text] [Related]
47. Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease.
Yanagimoto K; Nomura Y; Masuda K; Hirabayashi M; Morita Y; Yoshishige M; Ueno K; Eguchi T; Kawano Y
Int Arch Allergy Immunol; 2014; 164(2):83-8. PubMed ID: 24903098
[TBL] [Abstract][Full Text] [Related]
48. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance.
Ogihara Y; Ogata S; Nomoto K; Ebato T; Sato K; Kokubo K; Kobayashi H; Ishii M
Pediatr Res; 2014 Sep; 76(3):287-93. PubMed ID: 24964229
[TBL] [Abstract][Full Text] [Related]
49. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease.
Amano Y; Akazawa Y; Yasuda J; Yoshino K; Kojima K; Kobayashi N; Matsuzaki S; Nagasaki M; Kawai Y; Minegishi N; Ishida N; Motoki N; Hachiya A; Nakazawa Y; Yamamoto M; Koike K; Takeshita T
Pediatr Rheumatol Online J; 2019 Jul; 17(1):34. PubMed ID: 31269967
[TBL] [Abstract][Full Text] [Related]
50. Increased serum granulocyte colony-stimulating factor correlates with coronary artery dilatation in Kawasaki disease.
Samada K; Igarashi H; Shiraishi H; Hatake K; Momoi MY
Eur J Pediatr; 2002 Oct; 161(10):538-41. PubMed ID: 12297900
[TBL] [Abstract][Full Text] [Related]
51. Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease.
Hamada H; Suzuki H; Abe J; Suzuki Y; Suenaga T; Takeuchi T; Yoshikawa N; Shibuta S; Miyawaki M; Oishi K; Yamaga H; Aoyagi N; Iwahashi S; Miyashita R; Honda T; Onouchi Y; Terai M; Hata A
Cytokine; 2012 Dec; 60(3):681-5. PubMed ID: 22944461
[TBL] [Abstract][Full Text] [Related]
52. Kawasaki disease with lymphadenopathy and fever as sole initial manifestations.
Kubota M; Usami I; Yamakawa M; Tomita Y; Haruta T
J Paediatr Child Health; 2008 Jun; 44(6):359-62. PubMed ID: 18476929
[TBL] [Abstract][Full Text] [Related]
53. Value of neutrophil-lymphocyte ratio in predicting outcomes in Kawasaki disease.
Ha KS; Lee J; Jang GY; Lee J; Lee KC; Son CS; Lee JW
Am J Cardiol; 2015 Jul; 116(2):301-6. PubMed ID: 25975725
[TBL] [Abstract][Full Text] [Related]
54. [Comparison of efficacy among early, conventional and late intravenous gamma globulin treatment of Kawasaki disease].
Du ZD; Di Z; Du JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(26):1841-3. PubMed ID: 19953930
[TBL] [Abstract][Full Text] [Related]
55. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
Lee TJ; Kim KH; Chun JK; Kim DS
Yonsei Med J; 2008 Oct; 49(5):714-8. PubMed ID: 18972590
[TBL] [Abstract][Full Text] [Related]
56. Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease.
Inoue N; Takai S; Jin D; Okumura K; Okamura N; Kajiura M; Yoshikawa S; Kawamura N; Tamai H; Miyazaki M
Clin Chim Acta; 2010 Feb; 411(3-4):267-9. PubMed ID: 19945447
[TBL] [Abstract][Full Text] [Related]
57. Circulating adiponectin levels in Kawasaki disease.
Takeshita S; Takabayashi H; Yoshida N
Acta Paediatr; 2006 Oct; 95(10):1312-4. PubMed ID: 16982510
[TBL] [Abstract][Full Text] [Related]
58. [Dynamic study of platelets surface glycoprotein in Kawasaki disease].
Pang Y; Liang H; Yu S; Liu X; Wang Q; Tang F; Liu Y; Jiang L
Zhonghua Xue Ye Xue Za Zhi; 2002 Mar; 23(3):134-7. PubMed ID: 12015066
[TBL] [Abstract][Full Text] [Related]
59. Down-regulation of TLR2, 3, 9 and Signaling Mediators, MyD88 and TRIF, Gene Transcript Levels in Patients with Kawasaki Disease Treated with IVIG.
Mortazavi SH; Amin R; Alyasin S; Kashef S; Karimi MH; Babaei M; Younesi V
Iran J Allergy Asthma Immunol; 2015 Apr; 14(2):188-97. PubMed ID: 25780885
[TBL] [Abstract][Full Text] [Related]
60. TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease.
Hu P; Jiang GM; Wu Y; Huang BY; Liu SY; Zhang DD; Xu Y; Wu YF; Xia X; Wei W; Hu B
Clin Chim Acta; 2017 Aug; 471():76-80. PubMed ID: 28526535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
